Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance - Wikidata - wikimedia - TriplyDB

Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance

Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance

http://www.wikidata.org/entity/Q34225645

about

Inflammation and insulin resistance Exercise or exercise and diet for preventing type 2 diabetes mellitus 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study Hypoglycemic agents and potential anti-inflammatory activity Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention Type 2 diabetes and cognitive impairment: linking mechanisms Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force.Targeting inflammation in diabetes: Newer therapeutic options Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment Regenerative therapies for diabetic microangiopathy HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial.Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions.The prevention of type 2 diabetes.Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)EJE PRIZE 2017: Hypothalamic AMPK: a golden target against obesity?Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus.AMPK activation: a therapeutic target for type 2 diabetes?Metformin pharmacogenomics: current status and future directions.Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes.Effects of weight loss, weight cycling, and weight loss maintenance on diabetes incidence and change in cardiometabolic traits in the Diabetes Prevention Program.A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study.Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.Diabetes, related conditions, and dementia.Prevention of Diabetes Through the Lifestyle Intervention: Lessons Learned from the Diabetes Prevention Program and Outcomes Study and its Translation to Practice Effects of a community-based weight loss intervention on adipose tissue circulating factors Relationship of carotid intima-media thickness and duration of vegetarian diet in Chinese male vegetarians.Therapeutic approaches to target inflammation in type 2 diabetes Effect of vitamin D supplementation on insulin resistance and glycaemic control in prediabetes: a systematic review and meta-analysis.Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial.Obesity, Diabetes, the Cardiorenal Syndrome, and Risk for Cancer.Adiponectin, C-reactive protein, fibrinogen and tissue plasminogen activator antigen levels among glucose-intolerant women with and without histories of gestational diabetes Menopause and risk of diabetes in the Diabetes Prevention Program Diabetes mellitus and periodontal diseases.Incident hyperglycaemia among older adults with or at-risk for HIV infection.Antihyperglycemic, antihyperlipidemic, anti-inflammatory and adenosine deaminase- lowering effects of garlic in patients with type 2 diabetes mellitus with obesity.A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications.Relationship of body size and shape to the development of diabetes in the diabetes prevention program.Influence of lifestyle factors on inflammation in men and women with type 2 diabetes: results from the National Health and Nutrition Examination Survey, 1999-2004.

P2860

Q22241893-DB0B2434-1BCD-4351-91E1-9DA58386D1AE Q24241914-3DD98E4F-43A2-46BE-A110-D2AF23081DDC Q24633604-BC59589F-5E85-451B-B805-DAEFB45034D0 Q26750414-F91D621A-29B8-433A-933E-C339D5040DE2 Q26822066-F5AEE4A4-4B1A-4F92-9A35-C1D702732C6A Q26822993-263DFE67-E655-4B82-9D0D-ED167529131A Q26851536-C014A1F5-5214-4833-B688-671ED367DDC8 Q26852726-6FF2D1BB-CB8E-4022-9923-48D75449B389 Q26860246-B7485DB9-7244-467D-B2E5-2AFE09862C0E Q27027852-0B71592A-FECC-44D5-86D7-A5F61BB8C9F3 Q27335063-F214865F-4CA8-4676-B905-C8A83BF331FB Q28068120-5C6610EB-2C41-40E0-9CDE-4B1E564A83F7 Q30415102-D28CFAB6-F94F-40D9-9071-0D11B19F481B Q30484253-6C4F8DA2-3FD3-40A0-B086-FD064935CA78 Q30597265-3B3805DB-6162-4BC6-9AAD-1B95DD53F119 Q33556796-826619D3-F980-47E7-B090-BD4C6D7C5BF5 Q33660008-AA0F5B75-4C57-4E1A-93BE-E828BE541AF7 Q33763380-528DDC52-4F91-45AF-84DB-2401E5B97720 Q33824564-3C318638-BB19-49A6-8122-0B3AB6DBEE1B Q33959731-6FBED939-CFB2-4DED-9017-91399C26E865 Q33960260-5BF4D4DB-520F-47F1-A09C-B72ECD6E6E42 Q34219412-76E7F593-6873-4782-B141-A8ABE58B95DF Q34237273-884F0ABA-DF72-4584-8118-D94E2B3524A3 Q34294192-FED3F1BB-2D43-4993-86AD-697DD0816962 Q34361375-2F90B337-29D4-4127-9931-19313242D7C2 Q34459235-90E1F793-D38E-4223-BA6A-0D8FE08B020D Q34623147-64A5DC00-158E-40E1-9D5C-BA41F08EC0CB Q34632427-ECF63AEA-2610-49A0-9B7F-1DCF47C09FA0 Q35581498-2C47FFC3-C25E-4F32-898F-8A0D5C02E74C Q35755979-F498FCC2-EB0B-4C4A-B107-ED2AB57A8741 Q35930163-BD607B4A-D936-4E1E-BE9C-9B56073CD5A5 Q36035997-492CE2F3-3905-494C-8885-2A1BC2DD100A Q36277804-AEACA35C-7673-4C5A-A78E-BD5534E8C9DA Q36407356-967A909C-0690-4A00-A0ED-964C9F8D9032 Q36553573-13838D64-7614-412A-994B-596BDDEA57CA Q36554781-139CF609-DF2A-42C5-AF32-6FD9A63E8532 Q36560059-EC0220C7-ED6E-4E20-AB40-E964DD53C815 Q36596873-47C2AE0F-C902-4F49-8707-E9CED9CB38E6 Q36640356-85E7A89A-CC07-4D9C-A02F-DC8E40B4DEA3 Q36664090-252B0080-60BF-47FB-BC50-E1016BEA521E

P2860

Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance

http://www.wikidata.org/entity/Q34225645

description

2005 nî lūn-bûn

@nan

2005 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Intensive lifestyle interventi ...... ith impaired glucose tolerance

@ast

Intensive lifestyle interventi ...... ith impaired glucose tolerance

@en

Intensive lifestyle interventi ...... ith impaired glucose tolerance

@nl

type

label

Intensive lifestyle interventi ...... ith impaired glucose tolerance

@ast

Intensive lifestyle interventi ...... ith impaired glucose tolerance

@en

Intensive lifestyle interventi ...... ith impaired glucose tolerance

@nl

prefLabel

Intensive lifestyle interventi ...... ith impaired glucose tolerance

@ast

Intensive lifestyle interventi ...... ith impaired glucose tolerance

@en

Intensive lifestyle interventi ...... ith impaired glucose tolerance

@nl

P1433

Q34225645-0BF48631-522A-4AD9-B422-809BD1303C64

P1476

Q34225645-FC9DDEA1-7077-4C10-955C-596B404C358E

P2093

Q34225645-07230692-BE74-47CE-9CEC-E6D2061D695C

Q34225645-1FD4ED9D-35AA-44BC-A6FE-EA059D018E48

Q34225645-2B23D197-5285-4F47-8C24-47E4EBC9EB0E

Q34225645-2CBE3FF3-EA73-4829-8933-FDD27114CEA6

Q34225645-398DDBE0-0A96-4765-9360-F813C7567226

Q34225645-78E3C9FB-F3DA-49FC-94D4-DA74D38D0482

Q34225645-83ACA45F-2BEA-4194-9AFC-7F753507BE76

Q34225645-A0534CA5-044F-4257-BA4E-2D84034023B2

Q34225645-C4C45F26-3B46-4CCC-B08D-61A5284BDA7A

P2860

Q34225645-0103052C-34B4-43E0-95AC-25A68898B329

Q34225645-181814B6-D8CE-437D-80AD-9B07E7EA859C

Q34225645-1F7CD07F-1B07-4242-A021-BBD468FFF776

Q34225645-2192B0BC-2472-442E-A0B2-22435E965CD1

Q34225645-296B4FB3-D84F-4A51-B524-3CBB0A9BE503

Q34225645-2C2A4DAB-1460-4BAC-AABE-E43DC010FEE7

Q34225645-2F2F7F3E-A6E4-45B1-A8E5-AC657221393D

Q34225645-39F5C4DD-748D-4B3C-8DCB-C3CCD9538169

Q34225645-48CB3CC0-8B73-4B78-977F-6FFEBB1F69AE

Q34225645-56651B23-489F-46CC-B501-9C1D2096A846

P304

Q34225645-252B3F4D-2F38-4E59-AFE2-ED8B54E449CF

P31

Q34225645-943E3F10-2B2E-44DC-A957-403E4AB119E2

P356

Q34225645-9E9F48EB-BBFB-438A-95B0-A7FB0CFBC931

P407

Q34225645-750EB198-4448-444E-ADC4-203D042028DC

P433

Q34225645-29847AB1-F792-4569-8CFA-4DD48D3CCC44

P478

Q34225645-123248A5-03F0-4FB3-B401-5AA5CF137408

P50

Q34225645-1C8B961F-4A08-4536-95B9-64B57D70084B

Q34225645-B3EBC803-B1C5-4ACC-8260-84F9479FA006

Q34225645-F8BBBA29-7456-4681-BEFD-413C0FB09D6A

P577

Q34225645-BFF59358-6E48-4884-ADFE-2CD0EF385CCD

P5875

Q34225645-52A7BB54-55D2-4B2C-9531-B33020EE899B

P698

Q34225645-60B3DC95-6BCC-43C8-88F6-F2A254D05DED

P921

Q34225645-53e701b0-f432-4d35-8058-1afc621a4a28

Q34225645-D893ABCA-F2A9-4FC6-A8D4-2E78A0B0C5CF

P932

Q34225645-29D363FC-6BC9-4311-BC1E-FA458E2BBA44

P356

DIABETES.54.5.1566

P1433

P1476

Intensive lifestyle interventi ...... ith impaired glucose tolerance

@en

P2093

Edward Horton

http://www.w3.org/2001/XMLSchema#string

Jill Crandall

http://www.w3.org/2001/XMLSchema#string

Kieren Mather

http://www.w3.org/2001/XMLSchema#string

Marinella Temprosa

http://www.w3.org/2001/XMLSchema#string

Robert Ratner

http://www.w3.org/2001/XMLSchema#string

Ronald Goldberg

http://www.w3.org/2001/XMLSchema#string

Santica Marcovina

http://www.w3.org/2001/XMLSchema#string

Sarah Fowler

http://www.w3.org/2001/XMLSchema#string

Steven Haffner

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

Novel clinical markers of vascular wall inflammation

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss.

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.

Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies

P304

1566-1572

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DIABETES.54.5.1566

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Trevor J. Orchard

Elizabeth Barrett-Connor

Diabetes Prevention Program Research Group

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7883361

http://www.w3.org/2001/XMLSchema#string

P698

15855347

http://www.w3.org/2001/XMLSchema#string

P921

P932

1314967

http://www.w3.org/2001/XMLSchema#string